Clinical Lipidology, a companion to Braunwald's Heart Disease, is designed to guide you through the ever-changing therapeutic management of patients with high cholesterol levels. From basic science to pathogenesis of atherothrombotic disease, to risk assessment and the latest therapy options, this medical reference book offers unparalleled coverage and expert guidance on lipidology in a straightforward, accessible, and user-friendly style.
Get authoritative guidance from some of the foremost experts in the field.
Easily access key content with help from treatment algorithms.
Access options and evidence-based solutions for every type of patient scenario, as well as the latest clinical guidelines and clinically relevant evidence on risk assessment, special patient populations, and therapy, including recently approved and experimental therapies.
Remain at the forefront of the cardiology field with up-to-date chapters on treatment guidelines; diet, exercise, and weight loss; pharmacologic therapies such as statins, omega-3 fatty acids, and combination therapy; evolving targets of therapy such as PCSK9 inhibition, CETP inhibition, and inflammation
Prepare for special patient populations such as children and adolescents; women and the elderly; transplant recipients; HIV patients; and those with chronic renal disease, familial hypercholesterolemia, other severe hypercholesterolemias, diabetes, or other metabolic syndromes.
Take advantage of a format that follows that of the well-known and internationally recognized Braunwald's Heart Disease.
Expert Consult eBook version included with purchase.
Section 1 Basic Mechanisms 1. Human Plasma Lipoprotien Metabolism 2. Regulation and Clearance of Apolipoprotein B-Containing Lipoproteins 3. Absorption and Excretion of Intestinal Cholesterol and Other Sterols 4. High-Density Lipoprotein Metabolism 5. Lipoproteins: Mechanisms for Atherogenesis and Progression of Atherothrombotic Disease 6. Impact of Rare and Common Genetic Variants on Lipoprotein Metabolism 7. Lipoprotein Oxidation: Mechanisms and Biotheranostic Applications Section 2 Risk Assessment 8. Cholesterol: Concentration, Ratio, and Particle Number 9. High-Density Lipoprotein Cholesterol and Triglycerides in Coronary Heart Disease Risk Assessment 10. Lipoprotein(a) 11. Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia 12. Use of High Sensitivity C-Reactive Protein for Risk Assessment 13. Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease 14. Emerging Assays 15. Imaging Atherosclerosis for Risk Stratification by Cardiac Computed Tomography or Carotid Ultrasound Section 3 Therapy 16. Overview of General Approach to Management of Elevated Low-Density Lipoprotein Cholesterol and Mixed Dyslipidemia, High Triglycerides, and Low High-Density Lipoprotein Cholesterol 17. Treatment Guidelines Overview 18. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease 19. Exercise and Lipids 20. Weight Loss 21. Statins 22. Bile Acid Sequestrants 23. Cholesterol Absorption Inhibitors 24. Niacin (Nicotinic Acid) 25. Fibrates 26. Omega-3 Fatty Acids 27. Combination Therapy for Dyslipidemia 28. Nutriceuticals and Functional Foods for Cholesterol Reduction 29. Evolving Targets of Therapy: Cholesteryl Ester Transfer Protein Inhibition 30. Evolving Targets of Therapy: Proprotein Convertase Subtilisin/Kexin 9 Inhibition 31. Evolving Targets of Therapy: Inflammation as a Method to Predict and Prevent Cardiovascular Events 32. Invasive Imaging Modalities and Atherosclerosis: Intravascular Ultrasound 33. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound 34. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Magnetic Resonance Imaging and Positron Emission Tomography Imaging 35. Special Patient Populations: Diabetes and Metabolic Syndrome 36. Special Patient Populations: Women and Elderly 37. Special Patient Populations: Children and Adolescents 38. Special Patient Populations: Familial Hypercholesterolemia and other Severe Hypercholesterolemias 39. Special Patient Populations: Acute Coronary Syndromes 40. Special Patient Populations: Transplant Recipients 41. Special Patient Populations: Chronic Kidney Disease 42. Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups 43. Special Patient Populations: Human Immunodeficiency Patients 44. Therapeutic Targeting of High-Density Lipoprotein Metabolism